title: Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia.
abstract: Twenty-four patients aged 10.1 +/- 4.5 (mean +/- SD) years with recurrent paroxysmal supraventricular tachycardia underwent an electrophysiological study. Eleven patients had an overt and seven had a concealed accessory connection; six patients had no accessory connection. An orthodromic reciprocating tachycardia was inducible in 17 of 18 patients with an accessory connection, and an atrioventricular nodal reentrant tachycardia was inducible in four of six patients without accessory connection. After administration of propafenone, the sinus cycle length decreased. Intra-arterial, intranodal, and His-ventricle intervals and QRS duration increased. The atrial and ventricular effective refractory periods and anterograde and retrograde effective refractory periods of the atrioventricular node increased. The cycle length at which nodal second-degree block occurred increased. Of 18 patients with accessory connection, propafenone prolonged retrograde conduction in all, blocked anterograde conduction in five, and prolonged it in six. The drug terminated the orthodromic reciprocating tachycardia in all 17 patients and the atrioventricular nodal reentrant tachycardia in three of four patients. In three of four patients with atrioventricular nodal reentrant tachycardia and in 15 of 17 patients with orthodromic reciprocating tachycardia, the tachycardia was no longer inducible or nonsustained after propafenone. A follow-up of 26 +/- 10 months revealed that the drug when orally administered to all patients prevented recurrences of tachycardia in 15 of 18 patients with and in four of six patients without accessory connection. The results of short-term drug testing with propafenone predict the response to long-term oral therapy with this drug.
authors.affiliation: Division of Cardiology, Vincenzo Monaldi Hospital, Naples, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Musto
authors.forename: A
authors.initials: A
authors.lastname: D'Onofrio
authors.forename: C
authors.initials: C
authors.lastname: Cavallaro
authors.forename: A
authors.initials: A
authors.lastname: Musto
mesh_terms: D002304:Cardiac Pacing, Artificial; D002648:Child; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D008297:Male; D011405:Propafenone / Q000627:therapeutic use*; D012008:Recurrence; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy* / Q000503:physiopathology; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
chemical_list: D011405:Propafenone